Status:
UNKNOWN
Identification of Inflammatory Markers in Migraine Patients
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
Inflammation
Migraine
Eligibility:
All Genders
18-45 years
Brief Summary
Migraine is prevalent in 10-12% of the population. It involves the development of a cranial perivascular neurogenic inflammation. Recent information suggests that migraine might be a risk factor to st...
Detailed Description
Migraine is prevalent in 10-12% of the population, with female preponderance (1). Migraine may cause a significant distress and reduction of the quality of life of the patients, of whom in almost a th...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Men or women older than 18 years of age.
- Diagnosed with migraine, tension type headache or cluster headache according to International Headache Society criteria (24).
- Headache duration is at least 1 year prior to study entry.
- The frequency of migraine or tension type headache is 1-6 attacks in one month. Cluster headache duration is 2-4 weeks every year.
- No prior history of cerebral or cardiac vascular event.
- Exclusion criteria:
- Pregnant or breast feeding women.
- Subjects with permanent treatment with steroids.
Exclusion
Key Trial Info
Start Date :
September 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2011
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT00969995
Start Date
September 1 2009
End Date
December 1 2011
Last Update
September 2 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The headache clinic, Sourasky Medical Center Tel Aviv
Tel Aviv, Israel, 64239